Journal of Endocrinological Investigation

, Volume 27, Issue 3, pp 259–264 | Cite as

Effects of Graves’ ophthalmopathy on quality of life



General health-related quality of life is markedly impaired in patients with Graves’ ophthalmopathy (GO), and even worse than in patients with other chronic conditions like diabetes, emphysema or heart failure. A disease-specific quality-oflife questionnaire for GO has been developed, the so-called GO-QOL, consisting of two subscales: one for visual functioning (8 questions referring to limitations due to decreased visual acuity and/or diplopia) and one for appearance (8 questions referring to limitations in psychosocial functioning due to changes in appearance). The GO-QOL was found to be a valid and reliable instrument. A minimal clinically important difference (MCID) in the GO-QOL score was derived from data obtained before and after specific eye treatments. Based on the patient’s opinions, changes of ≥ 6 points (minor surgery) or ≥ 10 points (surgical decompression, immunosuppression) are recommended as MCID. It is concluded that the GO-QOL is an useful instrument for measuring changes over time in visual functioning and appearance of GO patients. The GO-QOL is available in six languages, and can be used as a separate outcome measure in clinical studies.


Graves’ ophthalmopathy quality of life GO-QOL 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Terwee CB. Graves’ ophthalmopathy through the eyes of the patient. Assessment of health-related quality of life. Ph.D. Thesis, University of Amsterdam, 2000.Google Scholar
  2. 2.
    Campbell A, Converse PE, Rodgers WL. The quality of American life. New York: Sage. 1976Google Scholar
  3. 3.
    Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996, 334: 835–40PubMedCrossRefGoogle Scholar
  4. 4.
    Prummel MF, Mourits MPh, Blank L, et al. Randomized double- blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993, 342: 949–54PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995, 273: 59–65PubMedCrossRefGoogle Scholar
  6. 6.
    Guyatt GH, Naylor D, Juniper E, et al. User’s guides to the medical literature. XII. How to use articles about health-related quality of life? JAMA 1997, 277: 1232–7PubMedCrossRefGoogle Scholar
  7. 7.
    Pinchera A, Wiersinga WM, Glinoer D, et al. Classification of eye changes of Graves’ disease. Thyroid 1992, 2: 235–6CrossRefGoogle Scholar
  8. 8.
    Prummel MF, Mourits MPh, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 1989, 321: 1353–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kahn JA, Doane JF, Whitacre MM. Does compression diminish the discomfort of severe dysthyroid orbitopathy? Ophthalm Plast Reconstruct Surg 1995, 11: 109–12CrossRefGoogle Scholar
  10. 10.
    Kung AWC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves’ ophthalmopathy. Thyroid 1996, 6: 381–4PubMedCrossRefGoogle Scholar
  11. 11.
    Fatourechi V, Garrity JA, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology 1994, 101: 938–42PubMedCrossRefGoogle Scholar
  12. 12.
    Kane RL, Maciesjewski M, Finch M. The relationship of patient satisfaction with care and clinical outcomes. Med Care 1997, 35: 714–30PubMedCrossRefGoogle Scholar
  13. 13.
    Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Aaronson NK, Muller M, Cohen PDA, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998, 51: 1055–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997, 7: 885–9PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart AL, Greenfield S, Wells K, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989, 262: 907–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002, 12: 237–39PubMedCrossRefGoogle Scholar
  18. 18.
    Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998, 82: 773–9PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy. J Clin Epidemiol 1999, 52: 875–84PubMedCrossRefGoogle Scholar
  20. 20.
    Terwee CB, Dekker FW, Mourits MPh, et al. Interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 2001, 54: 391–8CrossRefGoogle Scholar
  21. 21.
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989, 10: 407–15PubMedCrossRefGoogle Scholar
  22. 22.
    Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow- up of Graves’ ophthalmopathy in an incidence cohort. Ophthalmopathy 1996, 103: 958–62CrossRefGoogle Scholar
  23. 23.
    Terwee CB, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga WM. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002, 146: 751–7PubMedCrossRefGoogle Scholar
  24. 24.
    Sprangers MAG, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000, 53: 895–907PubMedCrossRefGoogle Scholar
  25. 25.
    Fayers P, Bjordal K. Should quality-of-life needs influence resource allocation? Lancet 2001, 357: 978PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2004

Authors and Affiliations

  • W. M. Wiersinga
    • 1
  • M. F. Prummel
    • 1
  • C. B. Terwee
    • 2
  1. 1.Department of Endocrinology and MetabolismAmsterdamThe Netherlands
  2. 2.Institute for Research in Extramural MedicineVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations